Case Studies & Articles
Niacinamide and Neuroprotection: The Glaucoma Holy Grail
Glaucoma—a degenerative optic neuropathy—is a leading cause of irreversible blindness. Experts estimate that this neurodegenerative disease will affect 112 million individuals worldwide. To date, all available therapies (medical, laser, and surgical) aim at the reduction of intraocular pressure (IOP) and none of the medical therapies aiming at neuroprotection have found much credence.
The International Workshop on Meibomian Gland Dysfunction: Report of the Subcommittee on Management and Treatment of Meibomian Gland Dysfunction
The goals of the subcommittee were to review the current practice and published evidence of medical and surgical treatment options for meibomian gland dysfunction (MGD) and to identify areas with conflicting, or lack of, evidence, observations, concepts, or even mechanisms where further research is required.
Papers & Publications
Carotenoids in the Management of Glaucoma: A Systematic Review of the Evidence
Glaucoma is an optic neuropathy that is characterized by progressive neurodegeneration of the inner retina, including the optic nerve head (ONH) and retinal nerve fiber layer (RNFL), resulting in loss of retinal ganglion cells (RGCs) and characteristic visual field defects. It remains the leading cause of irreversible vision loss globally and the projected prevalence of glaucoma is expected to reach 112 million in 2040.
Efficacy of Omega-3 Intake in Managing Dry Eye Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Dry eye disease (DED) is a common ocular disorder with multiple contributing factors. It is characterized by inadequate tear production, poor tear quality, or accelerated tear evaporation. The pathogenesis of DED includes tear film imbalances and ocular surface inflammation. These processes can result in symptoms such as dryness, excessive tearing, photophobia, and blurred vision.
Outcomes of the addition of oral administration of curcumin-phospholipid to hyaluronic acid-based tear substitute for the treatment of dry eye disease
The aim of this study is to report the clinical outcomes of oral supplementation with curcumin-phospholipid in addition to hyaluronic acid-based tear substitute for the management of dry eye disease (DED). Patients with a diagnosis of DED confirmed by pathological values of both NIKBUT <10 s. and OSDI Questionnaire score > 12 were included.
Effect of Ginkgo Biloba on Visual Field and Contrast Sensitivity in Chinese Patients With Normal Tension Glaucoma: A Randomized, Crossover Clinical Trial
Glaucoma is the second-leading cause of blindness in the world, accounting for an estimated 11.2 million bilaterally blind persons by the year 2020. Despite its high prevalence and the irreversible nature of the blindness it causes, glaucoma frequently remains undiagnosed and untreated in developing countries. While studies have shown glaucoma may be responsible for approximately 10% of blindness in Asia, only 10% of patients had been diagnosed and treated in a recent Indian study.
Glaucoma and Antioxidants: Review and Update
Glaucoma is a neurodegenerative disease characterized by slow and progressive apoptosis of retinal ganglion cells (RGCs) that affects more than 70 million people worldwide, making it one of the leading causes of irreversible blindness. Patients suffer from a centripetal loss of visual field associated with an increasing optic disc cupping, remaining asymptomatic until reaching advanced stages, which means that the number of affected individuals is much greater than those who know they have it.
Non-drug interventions in glaucoma: Putative roles for lifestyle, diet and nutritional supplements
Glaucoma is a major ocular neurodegenerative disease characterized by progressive retinal ganglion cell degeneration and sight loss. Current treatment options are limited to reducing intraocular pressure (IOP), which is the leading risk factor for this disease; however, glaucoma can develop even with low or normal IOP and can progress despite controlling IOP values.
The Roles of Vitamin D and Polyphenols in the Management of Age-Related Macular Degeneration: A Narrative Review
Age-related macular degeneration (AMD) is a chronic, progressive ocular disease that causes central vision loss. In Europe, AMD represents the main cause of severe visual impairment and blindness in the elderly. Approximately 67 million people worldwide are currently affected by this disease, and an increase by 15% in its prevalence is expected by 2050 in the European population. AMD is responsible for 8.7% of blindness throughout the world, and it is the main cause of visual impairment in developed countries in individuals aged 60 years or more.
Patient & Brochures
Doctor’s Advantage Macular Shield Brochure
Doctor-formulated Macular ShieldTM is designed for people who need extra support for the healthy functioning of the central eye region, or macula.*
Sales Brochures
Doctor’s Advantage CN2 Brochure
CN2 is made with ingredients to support healthy optic nerve function and blood flow.*
Cliradex Eyelid Cleansers
